Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Daily News

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

Todd Neale

December 26, 2025

News Daily News

As More Peripheral Interventions Go Radial, the AHA Offers Some Insights

L.A. McKeown

December 12, 2024

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

L.A. McKeown

May 10, 2024

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

The finding, from a study with a mean follow-up of 2-and-a-half years, bolsters support for trials and device use to continue.

News Daily News

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

L.A. McKeown

December 18, 2020

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

Caitlin E. Cox

January 24, 2020

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Daily News

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

Caitlin E. Cox

June 18, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Conference News VIVA 2018

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

L.A. McKeown

November 09, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

Advertisement

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

As More Peripheral Interventions Go Radial, the AHA Offers Some Insights

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

FDA’s First Take on New Paclitaxel Concerns in CLI

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

TCTMD’s Top 10 Most Popular Stories for January 2019

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content